Neuromod Secures €10 Million Boost for Tinnitus Treatment
Neuromod Devices Ltd., a pioneering Irish medical technology firm dedicated to tinnitus solutions, has successfully closed a significant equity financing round, securing €10 million. This financing will primarily be utilized to enhance the commercialization efforts for Lenire, its groundbreaking tinnitus treatment device.
Financing Overview
The recent funding round was led by current investors, Fountain Healthcare Partners and Panakès Partners. The oversubscribed nature of this financing underscores strong confidence in Neuromod's mission to improve tinnitus care.
Advancing Clinical Solutions
With this new capital, Neuromod aims to accelerate its commercial expansion across multiple markets, particularly in the United States and Europe. The company plans to leverage these funds to bolster availability and accessibility of Lenire, particularly focusing on veterans through engagement with the US Department of Veteran Affairs (USVA).
Innovative Treatment Device - Lenire
Lenire has made waves as the first non-invasive bimodal neuromodulation device designed to alleviate tinnitus symptoms. It functions by delivering mild electrical pulses to the tongue through its proprietary 'Tonguetip®', complemented with auditory stimulation via headphones. This multimodal approach has shown promising results in clinical settings.
Success in Clinical Settings
Since obtaining FDA approval, Lenire is available in over 100 clinics across the United States treating tinnitus patients. Its reception has also been favorable in Europe, with clinics across 14 countries embracing the device. Notably, the UK has seen a surge in trained clinics, effectively doubling within just six months.
Real-World Evidence and Impact
Real-world evidence is supporting Lenire's efficacy, with over 1,500 patients having reported significant improvements in symptoms. A recent analysis from an independent clinic demonstrated that 91.5% of participating patients experienced clinically significant relief from their tinnitus symptoms, aligning with the positive data derived from original clinical trials.
Comments from Leadership
Dr. Ross O'Neill, the founder and CEO of Neuromod, expressed enthusiasm about the financing, stating, "We are delighted to announce an oversubscribed financing at a pivotal time when we are driving forward with our mission of making Neuromod the category creator for tinnitus globally." He emphasized the urgency of addressing tinnitus as a major healthcare challenge, especially among veterans.
Dr. Manus Rogan, Chairman of Neuromod, remarked that based on recent patient feedback, Lenire represents a new standard of care for tinnitus treatment. He expressed confidence in the financing's role in extending these benefits to a larger patient population.
The Broader Picture of Tinnitus
Tinnitus remains a significant concern affecting approximately 15% of adults globally. The condition poses both a clinical and economic challenge, with estimates suggesting that healthcare systems incur massive costs related to its management. In the United States, veterans alone account for significant expenditures related to tinnitus care, illustrating the importance of effective treatment modalities.
About Neuromod Devices Ltd
Established in 2010 and based in Dublin, Ireland, Neuromod specializes in neuromodulation technologies aimed at addressing complex chronic conditions. Their flagship product, Lenire, is the culmination of extensive research and development, confirming its efficacy through rigorous clinical testing.
Frequently Asked Questions
What is Neuromod's main product?
Neuromod focuses on Lenire, a groundbreaking tinnitus treatment device utilizing bimodal neuromodulation technology.
How much funding did Neuromod secure?
Neuromod successfully closed €10 million in financing to enhance its treatment offerings for tinnitus.
Who led the financing for Neuromod?
The financing was led by existing investors, notably Fountain Healthcare Partners and Panakès Partners.
Where can Lenire be found?
Lenire is available in over 100 clinics in the United States and across several countries in Europe.
What are the implications of this funding?
This funding will help Neuromod increase the availability of Lenire and expand its reach, especially for veterans through partnerships with the US Department of Veteran Affairs.
